Olaparib (AZD2281): Selective PARP-1/2 Inhibitor for BRCA-Deficient Cancer Research

Executive Summary: Olaparib (AZD2281, Ku-0059436) is a nanomolar-range, selective inhibitor of PARP-1 and PARP-2, central to base excision repair and DNA damage response (APExBIO). It induces synthetic lethality in cells with homologous recombination deficiency, notably those with BRCA1/2 or BAP1 mutations (Borchert et al., 2019). Olaparib enhances radiosensitivity in preclinical NSCLC xenograft models by promoting DNA damage. The drug's efficacy and selectivity are benchmarked by gene expression profiling of HR pathway components. Its optimal use requires careful consideration of solubility, dosing, and storage constraints.

Biological Rationale

DNA double-strand break (DSB) repair is essential for genome stability. The homologous recombination repair (HRR) pathway repairs DSBs using a high-fidelity template. Tumors with defective HRR, termed 'homologous recombination deficiency' (HRD) or 'BRCAness', rely on alternative repair mechanisms, notably PARP-mediated base excision repair (BER) (Borchert et al., 2019). Inhibiting PARP-1/2 in these cells leads to persistent DNA damage, cell cycle arrest, and apoptosis. This selective vulnerability underpins the clinical and experimental use of PARP inhibitors such as Olaparib for BRCA-associated and HR-deficient cancers.

Mechanism of Action of Olaparib (AZD2281, Ku-0059436)

Olaparib is a competitive inhibitor of PARP-1 (IC₅₀ = 5 nM) and PARP-2 (IC₅₀ = 1 nM) (APExBIO). By binding to the catalytic domain of PARP enzymes, it blocks poly(ADP-ribosyl)ation of target proteins, preventing recruitment of DNA repair machinery. In HR-proficient cells, DSBs are repaired via HRR. In HR-deficient cells (e.g., with BRCA1/2, BAP1, or RAD51 mutations), PARP inhibition leads to unrepaired DNA lesions, resulting in mitotic catastrophe and cell death. Olaparib also induces 'PARP trapping', wherein inhibited PARP enzymes remain bound to DNA, further impeding repair. Radiosensitization is achieved by augmenting DNA damage under radiation, as demonstrated in NSCLC xenograft models (Related Article).

Evidence & Benchmarks

• Olaparib induces apoptosis and senescence in BAP1-mutated mesothelioma cell lines under 10 μM, 1-hour treatment in vitro (Borchert et al., 2019).
• BAP1 loss-of-function mutation is present in 26–64% of malignant pleural mesotheliomas, correlating with HRD and Olaparib sensitivity (Borchert et al., 2019).
• PARP inhibition efficacy is not restricted to BRCA1/2 mutations but extends to other HR pathway defects, including BAP1 and RAD51 (Borchert et al., 2019).
• Gene expression levels of AURKA, RAD50, and DDB2 can serve as predictive markers for Olaparib response in MPM (Borchert et al., 2019).
• Olaparib at 50 mg/kg/day intraperitoneally for 14 days is well-tolerated in mouse tumor models (APExBIO).
• ATM-deficient cells exhibit increased sensitivity to PARP inhibition, supporting ATM status as a biomarker (Related Article).

Applications, Limits & Misconceptions

Olaparib is extensively used for:

• DNA damage response assays and investigation of PARP-mediated repair.
• Tumor radiosensitization studies, particularly in NSCLC and BRCA-deficient xenograft models (see contrasting mechanistic insights).
• Targeted therapy research for BRCA-associated and HR-deficient cancers, including ovarian, breast, prostate, and mesothelioma (see expanded review of resistance mechanisms).
• Translational studies integrating gene signature profiling for personalized medicine (strategic integration guidance).

Common Pitfalls or Misconceptions

• Olaparib is not effective in tumors with fully functional HRR pathways (e.g., wild-type BRCA1/2 and BAP1).
• Long-term storage of stock solutions at room temperature or above -20°C leads to compound degradation and experimental variability.
• Solubility is limited in ethanol and water; DMSO is required for stock preparation (≥21.72 mg/mL).
• PARP inhibition does not universally sensitize all tumor types to radiation; context-dependent gene expression modulates effect.
• Resistance mechanisms, such as restoration of HRR or upregulation of drug efflux pumps, can emerge in prolonged studies.

Workflow Integration & Parameters

Researchers should prepare Olaparib (AZD2281, Ku-0059436, APExBIO A4154) as a stock solution in DMSO at concentrations ≥21.72 mg/mL. For in vitro studies, typical conditions are 10 μM for 1 hour in cell culture. For in vivo mouse models, 50 mg/kg/day intraperitoneally for 14 days is standard. Store aliquots below -20°C and avoid repeated freeze-thaw cycles. Evaluate HRD status (BRCA1/2, BAP1, RAD50) via gene expression profiling prior to application. Incorporate appropriate controls (vehicle, PARP-proficient cells) and monitor markers of apoptosis (e.g., caspase signaling) and DNA damage (e.g., γ-H2AX foci).

Conclusion & Outlook

Olaparib (AZD2281) is a validated, selective PARP-1/2 inhibitor that enables targeted research into DNA repair, radiosensitization, and synthetic lethality in BRCA- and HR-deficient cancers. Its use is supported by robust mechanistic and translational evidence, as detailed in both peer-reviewed literature (Borchert et al., 2019) and product documentation (APExBIO). Strategic integration with gene signature profiling and careful workflow design will maximize its impact in preclinical research. For a systems-biology perspective on BRCAness and translational assay design, see this article, which this dossier updates with quantitative benchmarks and workflow recommendations.